Key Points
BERLIN, Nov 16 (Reuters) - U.S. pharmaceuticals company Eli Lilly (LLY.N) plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros..
The company declined to comment on the plans but news conferences are planned in Alzey, where sources say the plant will be built, and Berlin on Friday...
The project will be fully funded by the medicines giant, which has seen surging demand for its diabetes drug Mounjaro, now also being used off-label for weight loss, people familiar with the matter had told Reuters on Wednesday...
Other recent investments in the country, including chip plants by the U.S.'s Intel and Taiwan's TSMC, were won with the promise of massive public subsidies, making Lilly's fully-funded investment potentially a more positive story for the government...
Indianapolis-based Eli Lilly and Danish rival Novo Nordisk (NOVOb.CO) are ahead in a race to grab a slice of an estimated $100 billion global market for anti-obesity treatments from a class of drugs originally developed for diabetes known as GLP-1 agonists...
You might be interested in
Novo, Lilly rivals explore booming weight-loss drug market entry
08, Dec, 23Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.
Weight loss without Wegovy’s side-effects on biotech firms' radar
07, Jul, 23Weight-loss drug Wegovy helped Rebecca Vogt achieve a major goal - shedding the weight she had not managed to drop since giving birth. But, after a particularly brutal day in the bathroom suffering from vomiting and diarrhoea, she called it quits.
Has a 'magical' weight loss drug finally arrived? Hopes soar with US firm's never-before-seen results
29, Jun, 23Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
Lilly to build $2.5 bln diabetes drug plant in Germany
17, Nov, 23Eli Lilly (LLY.N) will build its first plant in Germany for 2.3 billion euros ($2.5 billion) in the western town of Alzey, the U.S. pharmaceuticals maker said on Friday, as the sector scrambles to meet demand for new diabetes and obesity therapies.
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).
Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market
05, May, 23The enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.
Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
27, Jun, 23Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.
Weight loss drugs transforming healthcare, may help with addiction
09, Nov, 23A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week.
TCS CEO on jobs scandal, $2 billion deal cancellation & more; Byju’s announces key appointments
14, Jul, 23OK, Tata. A day after Indias largest tech company Tata Consultancy Services (TCS) kicked off the earnings season with subdued numbers, CEO & MD K Krithivasan sat down with ETtech, talking about everything from the latest recruitment scandal in the company to macroeconomic indicators. This and more in todays ETtech Morning Dispatch.
Lilly cuts annual profit view on acquisition charges despite Mounjaro beat
02, Nov, 23Eli Lilly (LLY.N) on Thursday cut its full-year adjusted earnings outlook owing to charges related to its recent acquisitions, even as its popular diabetes drug Mounjaro brought in a billion dollars in quarterly sales.